Research
Hormonal
Tirzepatide, a GLP-1/GIP receptor co-agonist, is approved for type 2 diabetes and shows significant reductions in glycemia and body weight compared to GLP-1R mono-agonism with semaglutide.
Tirzepatide may be a more effective treatment option for managing blood sugar and weight in patients with type 2 diabetes.
StrongSupportsmedium confidence
Phase 3 trials in T2D cohorts revealed significant reductions in glycemia and body weight and superiority compared with GLP-1R mono-agonism with semaglutide.
Why this rating
Based on phase 3 trial data.
Source
Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data
Ronald Goldenberg et al. · Current Opinion in Cardiology · 2023
reviewCited 12×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →